Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Neuromyelitis Optica (NMO) is a rare, devastating demyelinating disease of the central
nervous system (CNS) that has different causes and treatments from the more common
demyelinating disease multiple sclerosis (MS). Current NMO therapies are nonspecific and have
varying and often suboptimal benefit. The investigators will evaluate whether use of
alpha1-antitrypsin (A1AT, an FDA-approved medication for patients with congenital deficiency
of A1AT associated with emphysema) can benefit acute attacks of NMO, improving patient
disability and quality of life.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
Alpha 1-Antitrypsin Methylprednisolone Methylprednisolone acetate Methylprednisolone Hemisuccinate Prednisolone Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate Protease Inhibitors Protein C Inhibitor